NASDAQ:RKDA

Arcadia Biosciences Stock Forecast, Price & News

$2.35
-0.06 (-2.49 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.34
$2.46
50-Day Range
$2.31
$3.10
52-Week Range
$2.26
$6.40
Volume110,499 shs
Average Volume1.80 million shs
Market Capitalization$50.14 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.68
30 days | 90 days | 365 days | Advanced Chart
Receive RKDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Arcadia Biosciences logo

About Arcadia Biosciences

Arcadia Biosciences, Inc. engages in developing various crop productivity traits primarily in hemp, wheat, and soybean. The company's crop productivity traits are designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. Its products include GoodHemp, a commercial pipeline of non-GMO hemp seed varieties developed with modern crop innovation tools focused on genetic improvement of hemp; GoodWheat that redesigns wheat as a functional food adding value to the wheat supply chain by enabling a range of choices to meet consumer demands; and nutritional oils, such as gamma linolenic acid oils. The company has collaborations with Ardent Mills, LLC, Corteva AgriScience, and Arista Cereal Seeds Pty Ltd, and Bay State Milling Company. It operates in the United States, Argentina, Canada, Africa, Austria, and India. The company was incorporated in 2002 and is headquartered in Davis, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.51 out of 5 stars

Basic Materials Sector

283rd out of 919 stocks

Agricultural Production - Crops Industry

8th out of 22 stocks

Analyst Opinion: 3.5Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions

Is Arcadia Biosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Arcadia Biosciences stock.
View analyst ratings for Arcadia Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Arcadia Biosciences?

Wall Street analysts have given Arcadia Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcadia Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arcadia Biosciences' next earnings date?

Arcadia Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Arcadia Biosciences
.

How were Arcadia Biosciences' earnings last quarter?

Arcadia Biosciences, Inc. (NASDAQ:RKDA) issued its earnings results on Sunday, May, 16th. The basic materials company reported $0.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.34) by $0.46. The basic materials company earned $0.83 million during the quarter, compared to the consensus estimate of $0.85 million. Arcadia Biosciences had a negative net margin of 47.27% and a negative trailing twelve-month return on equity of 61.18%.
View Arcadia Biosciences' earnings history
.

How has Arcadia Biosciences' stock been impacted by COVID-19?

Arcadia Biosciences' stock was trading at $3.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RKDA shares have decreased by 25.9% and is now trading at $2.35.
View which stocks have been most impacted by COVID-19
.

When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?

Shares of Arcadia Biosciences reverse split before market open on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for RKDA?

2 Wall Street analysts have issued 1 year price objectives for Arcadia Biosciences' shares. Their forecasts range from $4.50 to $7.00. On average, they expect Arcadia Biosciences' stock price to reach $5.75 in the next year. This suggests a possible upside of 144.7% from the stock's current price.
View analysts' price targets for Arcadia Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Arcadia Biosciences' key executives?

Arcadia Biosciences' management team includes the following people:
  • Mr. Matthew T. Plavan, Pres, CEO & Director (Age 57, Pay $468.51k)
  • Ms. Pamela Haley, CFO & Corp. Sec. (Age 50, Pay $271.8k)
  • Ms. Belinda Yao, VP of Operations
  • Mr. Christopher Williams-Campbell, Head of People
  • Ms. Gia Fazio Ph.D., Chief of Staff
  • Mr. Chris Cuvelier, Chief Growth Officer (Age 52)
  • Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 55)
  • Mr. Kevin Hodges, VP of Commercial Operations

What is Matthew Plavan's approval rating as Arcadia Biosciences' CEO?

1 employees have rated Arcadia Biosciences CEO Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among Arcadia Biosciences' employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcadia Biosciences' key competitors?

What other stocks do shareholders of Arcadia Biosciences own?

When did Arcadia Biosciences IPO?

(RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

What is Arcadia Biosciences' stock symbol?

Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."

How do I buy shares of Arcadia Biosciences?

Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcadia Biosciences' stock price today?

One share of RKDA stock can currently be purchased for approximately $2.35.

How much money does Arcadia Biosciences make?

Arcadia Biosciences has a market capitalization of $50.14 million and generates $8.03 million in revenue each year. The basic materials company earns $-4,660,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How many employees does Arcadia Biosciences have?

Arcadia Biosciences employs 58 workers across the globe.

What is Arcadia Biosciences' official website?

The official website for Arcadia Biosciences is www.arcadiabio.com.

Where are Arcadia Biosciences' headquarters?

Arcadia Biosciences is headquartered at 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018.

How can I contact Arcadia Biosciences?

Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]


This page was last updated on 7/30/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.